WR 151327

Drug Profile

WR 151327

Alternative Names: NSC 327729; NSC 335662

Latest Information Update: 15 Oct 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source; Southern Research Institute
  • Developer MedImmune Oncology; Nonindustrial source
  • Class Antivirals; Radioprotectives
  • Mechanism of Action Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage; HIV infections

Most Recent Events

  • 15 Oct 2004 Discontinued - Preclinical for Chemotherapy induced damage in USA (PO)
  • 15 Oct 2004 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 15 Feb 2000 A preclinical study has been added to the Cancer pharmacodynamics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top